Testing a new drug for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This early-phase trial tests a new oral drug, GT-220F, for men whose prostate cancer has spread and no longer responds to hormone therapy. It may be especially for patients whose cancer has specific genetic changes in the PTEN or PIK3CB genes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man age 18 or older.
- Your prostate cancer has spread and does not respond to standard hormone therapy.
- You have tried at least one targeted hormone therapy (like enzalutamide or abiraterone).
- You are still taking hormone therapy to lower your testosterone, or had your testicles removed.
- You have not taken a PI3K inhibitor drug before (like idelalisib).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called FG-3246, which targets a protein (CD46) on prostate cancer cells. It's for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy, and who have had limited prior treatments.
This trial tests a new radioactive treatment, [225Ac]Ac-FL-020, for men with metastatic castration-resistant prostate cancer (mCRPC) that has gotten worse despite other treatments. It's for those who have had at least one prior hormone therapy or chemotherapy.
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
This trial tests an experimental tablet called TQB3201 for men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapies. The study aims to find the right dose and see how well the drug works.
This trial tests a new drug called KTX-2001, possibly combined with another drug (darolutamide), for men whose prostate cancer has spread and stopped responding to standard hormone treatments. The goal is to see if it can help shrink tumors or slow the cancer's growth.
This study tests an experimental drug for men whose prostate cancer has spread and stopped responding to standard hormone therapies. It may be an option if your PSA is rising despite treatment with drugs like enzalutamide or abiraterone.
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.